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Background: In Oncology, the resistance of the cancerous cells to chemotherapy continues to be the principal
limitation. The nuclear factor-kappa B (NF-κB) transcription factor plays an important role in tumor escape and
resistance to chemotherapy and this factor regulates several pathways that promote tumor survival including some
antiapoptotic proteins such as Bcl-2 and Bcl-XL. In this study, we investigated, in U937 human leukemia cells, the
effects of PTX and the MG132 proteasome inhibitor, drugs that can disrupt the NF-κB pathway. For this, we
evaluated viability, apoptosis, cell cycle, caspases-3, -8, -9, cytochrome c release, mitochondrial membrane potential
loss, p65 phosphorylation, and the modification in the expression of pro- and antiapoptotic genes, and the Bcl-2
and Bcl-XL antiapoptotic proteins.
Results: The two drugs affect the viability of the leukemia cells in a time-dependent manner. The greatest
percentage of apoptosis was obtained with a combination of the drugs; likewise, PTX and MG132 induce G1 phase
cell cycle arrest and cleavage of caspases -3,-8, -9 and cytochrome c release and mitochondrial membrane potential
loss in U937 human leukemia cells. In these cells, PTX and the MG132 proteasome inhibitor decrease p65 (NF-κB
subunit) phosphorylation and the antiapoptotic proteins Bcl-2 and Bcl-XL. We also observed, with a combination of
these drugs overexpression of a group of the proapoptotic genes BAX, DIABLO, and FAS while the genes BCL-XL,
MCL-1, survivin, IκB, and P65 were downregulated.
Conclusions: The two drugs used induce apoptosis per se, this cytotoxicity was greater with combination of both
drugs. These observations are related with the caspases -9, -3 cleavage and G1 phase cell cycle arrest, and a
decrease in p65 phosphorylation and Bcl-2 and Bcl-XL proteins. As well as this combination of drugs promotes the
upregulation of the proapoptotic genes and downregulation of antiapoptotic genes. These observations strongly
confirm antileukemic potential.
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Leukemia is a heterogenic group of diseases characterized
by infiltration of neoplastic cells of the hematopoietic sys-
tem into the blood, bone marrow, and other tissues [1,2].
Leukemia is the most common malignancy among people
aged <20 years. In the last decade, these diseases have
exhibited a clear ascending pattern in the morbidity index,
becoming a great challenge to health institutions [3].
The main treatment for this disease is chemotherapy.
However, its results are very often limited due to the
treatment resistance that the neoplastic cells develop
[4,5]. In an attempt to increase the efficiency of antileu-
kemic treatments, higher doses of the cytotoxic agents
have been used or different combinations of them [6,7],
but in the majority of the cases, higher doses have been
put into effect in an empirical manner without good re-
sults and incrementing side effects.
Given this situation, our research team has developed
the concept of chemotherapy with a rational molecular
basis. The former is based on the premise that chemo-
therapy acts mainly to induce a genetically programmed
death of the cell called apoptosis, and that this depends
in turn on the synthesis of proteins de novo and the acti-
vation of biochemical factors as a result of a modifica-
tion in the balance between expression of pro- and
antiapoptotic genes in response to treatment [8,9]. The
cells undergoing apoptosis show internucleosomal frag-
mentation of the DNA, followed by nuclear and cellular
morphologic alterations, which leads to a loss of the in-
tegrity of the membrane and the formation of apoptotic
bodies. All of these processes are mediated by caspases,
which are the main enzymes that act as apoptosis initia-
tors and effectors. Some of these molecules can active
themselves, while others require other caspases in order to
acquire biological activity. This proteolytic cascade breaks
down specific intracellular proteins including nuclear pro-
teins of the cytoskeleton, endoplasmic reticulum, and
cytosol, finally hydrolyzing the DNA [10-12].
On the other hand, it is noteworthy that upon apop-
totic stimulus such as that generated by chemotherapy,
this not only induces apoptosis but can also activate
antiapoptotic mechanisms [13,14]. Similarly, the nuclear
factor-kappa B (NF-κB) transcription factor plays an im-
portant role in tumor cell growth, proliferation, invasion,
and survival. In inactive cells, this factor is linked with
its specific inhibitor I-kappa B (IκB), which sequesters
NF-κB in the cytoplasm and prevents activation of target
genes [15-18]. In this respect, NF-κB can activate
antiapoptotic genes such as Bcl-2, Bcl-XL, and survivin,
affecting chemotherapy efficiency, even if the chemo-
therapy itself or the radiotherapy itself can activate the
NF-κB factor [19-21]. Blast cells exhibit overexpression
of antiapoptotic proteins (Bcl-2 and Bcl-XL), which in-
crease resistance to antitumor therapy [22].In this regard, the drug PTX can prevent the phosphor-
ylation of serines 32 and 36 of IκB, and we have found that
PTX in combination with antitumor drugs such as
adriamycin and cisplatin induced in vitro and in vivo a sig-
nificant increment of apoptosis in fresh leukemic human
cells [8], lymphoma murine models [9], and cervical can-
cer cells [23]. Similar results have also been observed with
PTX in other studies [24]. PTX is a xanthine and a com-
petitive nonselective phosphodiesterase inhibitor that in-
hibits tumor necrosis factor (TNF) and leukotriene
synthesis and reduces inflammation [25,26]. The MG132
proteasome inhibitor is another drug that decreases NF-
κB activity [27]. Proteasome inhibitors are becoming pos-
sible therapeutic agents for a variety of human tumor
types that are refractory to available chemotherapy and
radiotherapy modalities [28,29]. The proteasome is a
multicatalytic complex that is responsible for regulating
apoptosis, cell cycle, cell proliferation, and other physio-
logical processes by regulating the levels of important sig-
naling proteins such as NF-κB, IκB, and the MG132
proteasome inhibitor have been shown to induce apop-
tosis in tumor cells [30,31]. This is important because
apoptosis is regulated by the ubiquitin/proteasome system
at various levels [32]. The aim of the present work was to
study in vitro in U937 leukemic cells the effects on viabil-
ity, apoptosis, cell cycle, caspases cleavage, cytochrome c
release and mitochondrial membrane potential (ΔΨm),
the Bcl-2 and Bcl-XL antiapoptotic proteins, and related
genes activated by the PTX and/ or MG132 proteasome
inhibitor, compounds that possess a NF-κB-mediated in-
hibitory effect.Methods
Cells
The cell line U937 (ATCC CRL-1593.2), human mono-
cytic leukemia, was used. These cells were cultivated in an
RPMI-1640 culture medium (GIBCO, Invitrogen Co.,
Carlsbad, CA, USA) with the addition of 10% fetal bovine
serum (FBS) (GIBCO), a 1% solution of L-glutamine 100X
(GIBCO), and antibiotics (GIBCO), which will be desig-
nated as RPMI-S. The cells were maintained at 37°C in a
humid atmosphere containing 5% CO2 and 95% air.Drugs
PTX (Sigma-Aldrich, St. Louis, MO, USA) was dissolved
in a sterile saline solution (0.15 M) at a 200 mM concen-
tration and stored at ‒4°C during a maximum period of 1 -
week. The MG132 proteasome inhibitor (N-CBZ-LEU-
LEU-AL, Sigma-Aldrich) 0.5 mg was dissolved in
0.250 mL of Dimethyl sulfoxide (DMSO, Sigma-Aldrich),
divided into 20 μL aliquots, and stored at ‒20°C. Immedi-
ately prior to use, this was diluted in RPMI-1640 culture
medium at a final concentration of 1 μM.
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U937 cells (2.5 × 105-mL in T75 flasks, Corning Incor-
porated, Corning, NY, USA) were grown in RPMI-S for
24 hours and collected by centrifugation. The cells were
reseeded onto 24 well plates; U937 cells were either
treated with PTX (8 mM) or MG132 (1 μΜ), or PTX +
MG132 (final concentrations). The cells were incubated
with PTX for 1 hour prior to the addition of MG132.
All experiments were carried out 24 hours after treat-
ment, to exception of the p65 phosphorylation that it
was analyzed 1 hour after treatment with PTX or
MG132 and in the gene expression studies the cells
were incubated with the drugs for only 3 hours. The
concentrations of the treatments employed in this study
were previously confirmed as being the most favorable
for the induction of apoptosis in this experimental
model [33,34].
Cellular viability
Cell viability was determined at different times in U937
cells (2 X 104). They were incubated with PTX, MG132
or PTX +MG132 during 18, 24, 36 and 48 hours, we use
a WST-1 cell proliferation reagent commercial kit
(BioVision, Inc. Milpitas, CA, USA) following the manu-
facturer’s instructions. This study is based on the reduc-
tion of tetrazolium salts (WST-1) to formazan. After of
the incubation 10 μL/well of WST-1/ECS reagent was
added and the U937 cell were incubated for another 3 -
hours. The absorbance was measured in a microplate
reader (Synergy™ HT Multi-Mode Microplate Reader;
Biotek, Winooski, VT, USA) at 450 nm as reading refer-
ence wavelength at 690 nm. Data are reported as the
mean ± standard deviation of the optical density values
obtained in each group.
Cell cycle analysis by flow cytometry
For cell cycle analysis, the U937 cells were synchronized
[35]. In brief, cells were culture in RPMI-1640
containing 5% FBS by 12 hours then the cells were
washed and culture in RPMI-1640 containing 1% FBS
overnight. After the cells were washed with PBS and
changed to serum free medium for 18 hours, and finally
the cells were passage and released into cell cycle by
addition of 10% FBS in RPMI-1640 culture medium and
1 × 106 cells were treated 24 hours with the different
drugs. The BD Cycletest™ Plus DNA Reagent Kit was
used following the manufacturer’s instructions (BD Bio-
sciences, San Jose, CA, USA). DNA QC Particles (BD
Biosciences) were used for verification of instrument
performance and quality control of BD FACSAria I (BD
Biosciences) cell sorter employed in DNA analysis. For
each sample, at least 20,000 events were acquired and
data were processed with Flowjo v7.6.5 software (Tree
Star Inc., OR, USA).Assessment of apoptosis induction by PTX and MG132
proteasome inhibitor
Apoptosis was evaluated by means of the Annexin
V-FITC FLUOS Staining kit (Annexin-V-Fluos; Roche,
Mannheim, Germany). Briefly, 1×106 U937 cells were
treated 24 hours with PTX, MG132 or PTX+MG132 after
that the samples were washed twice with PBS and
resuspended in 100 μL of incubation buffer; 2 μL of
Annexin V- Fluorescein Isothiocyanate (FITC) and 2 μL of
propidium iodide (PI) solution were added. The samples
were mixed gently and incubated for 10 min at 20°C in the
dark. Finally, 400 μL of incubation buffer was added to
each suspension, which was analyzed by flow cytometry.
Annexin V- FITC-negative and PI-negative cells were con-
sidered live cells. Percentage of cells positive for Annexin
V-FITC but negative for PI was considered to be in early
apoptosis. Cells positive for both Annexin V-FITC and PI
were considered to be undergoing late apoptosis and cells
positive to PI were considered to be in necrosis. At least
20,000 events were acquired with the FACSAria I cell
sorter and analysis was performed using FACSDiva soft-
ware (BD Bioscience).
Assessment of mitochondrial membrane potential by flow
cytometry
U937 cells (1 × 106) were treated 24 hours with the differ-
ent drugs after that the cells were washed twice with PBS,
resuspended in 500 μL of PBS containing 20 nM of 3,3-
dihexyloxacarbocyanine iodide (DIOC6, Sigma-Aldrich),
and incubated at 37°C for 15 min and the percentage of
cells with ΔΨm loss was analyzed by flow cytometry. As
an internal control of the disrupted ΔΨm, cells were
treated for 4 hours with 150 μM of protonophore carbonyl
cyanide m-chlorophenylhydrazone (CCCP, Sigma-Adrich)
positive control. Flow cytometry was performed using
FACSAria I (BD Biosciences). At least 20,000 events were
analyzed with the FACSDiva Software (BD Biosciences) in
each sample.
Protein extraction for caspases-3, -8 and -9 and
cytochrome c and Western blot assay
U937 cells (5 × 106) were treated with PTX, MG132 and
PTX +MG132 for 24 hours. After treatment, cells were
harvested, washed twice with PBS and lysed with RIPA
buffer (0.5% deoxycholate, 0.5% NP-40, 0.5% SDS, 50 mM
Tris pH 7.4 and 100 mM NaCl) containing protein inhibi-
tors. Following sonication (15 pulses, 50% amp), protein
extracts were obtained after 30 min incubation at 4°C and
5 min of centrifugation at 14,000 rpm/4°C. Protein con-
centrations were determined using Dc Protein Kit (Bio-
Rad Laboratories, Inc., CA, USA). Total cell protein
(40 μg) was subjected to electrophoresis using a 10%
sodium dodecyl sulfate (SDS) polyacrylamide gel. Subse-
quently, proteins were transferred to Immobilon-P PVDF
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with 1× Western blocking reagent (Roche) during 1.5 hour
for nonspecific binding. Immunodetection of caspases-3, -
8 and -9 were performed using anti-caspases -3, -8 and -9
antibodies (BioVision, Inc.) and cytochrome c was effected
using anti-cytochrome c antibody (Biolegend, San Diego,
CA, USA) at 4°C overnight. After incubation with a horse-
radish peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology, CA, USA) immunoreactive proteins
were visualized by Western blotting luminol reagent using
the ChemiDoc™ XRS equipment (Bio-Rad) with the
Quantity OneW 1-d Analysis Software (Bio-Rad). Control
β-actin antibody (Santa Cruz Biotechnology). Protein
levels on Western blot were quantified using the IMAGEJ
1.46r package (NIH, Bethesda, MD, USA).
Detection of Bcl-2 and Bcl-XL antiapoptotic proteins, and
p65 phosphorylation by flow cytometry
For determination of Bcl-2, Bcl-XL, and phosphorylated
p65, 1 × 106 U937 cells were treated or not treated for 1 -
hour with PTX, MG132 or PTX +MG132. We employed
Alexa FluorW 647mouse anti-human Bcl-2 and Alexa
FluorW 647 mouse anti human Bcl-XL proteins (Santa
Cruz Biotechnology) and Alexa FluorW 647 mouse anti-
human NF-κB p65 (pS529) (BD Biosciences) antibodies.
The staining procedures were according to protocol for
detecting protein or activation of the phosphorylation
state by flow cytometry. An appropriate isotype control
was utilized in each test to adjust for background fluor-
escence, and the results are represented as the mean
fluorescence intensity (MFI) of Bcl-2, Bcl-XL proteins,
and phosphorylated p65 protein. For each sample, at
least 20,000 events were acquired in a FACSAria I cell
sorter (BD Biosciences) and data were processed with
FACSDiva software (BD Biosciences).
Quantitative real-time PCR
Total RNA of the U937 cells (5×106) was obtained after 3 -
hours of incubation with the different treatments using
the Purelink™ Micro-to-Midi purification system for total
RNA (Invitrogen Co.). The DNAc was synthesized begin-
ning with 5 μg of total RNA utilizing the Superscript™ III
First-Strand Synthesis Supermix kit (Invitrogen Co.). Real-
Time PCR was carried out with the System Light CyclerW
2.0 (Roche Applied Science, Mannheim, Germany), for
which we employed DNA Master plus SYBR Green I
(Roche Applied Science). The PCR program consisted of
an initial 10-min step at 95°C, and 40 cycles of 15-sec at
95°C, 5-sec at 60°C, and 15-sec cycles at 72°C. Analysis of
the PCR products was carried out with Light CyclerW soft-
ware (Roche Applied Science). Data are presented in rela-
tive normalized quantities employing L32 ribosomal gene
expression to verify the specificity of the amplified reac-
tion, which was nearly 100%. The oligonucleotides(Invitrogen Co.) were designed in the data base of nucleo-
tides of the Gen Bank of the National Information Center
for Biotechnology (http://www.ncbi.nlm.nih.gov) using the
oligo v.6 program (Table 1).
Statistical analysis
All experiments were carried out in triplicate and were
repeated three times. The values represent mean ±
standard deviation of the values obtained. Statistical ana-
lysis was performed with the non-parametric Mann-
Whitney U test considering p <0.05 as significant. In
some experiments, we calculated the Δ%, which repre-
sents the percentage of increase or diminution in rela-
tion to the corresponding untreated control group
(UCG). For the different gene expressions, we consid-
ered significant variations as ≥ at 30% compared with the
constitutive gene [8].
The committee of ethics, biosafety and research of CIBO
approved the study with the number 1305-2005-16.
Results
PTX and MG132 proteasome inhibitor induce a decrease
in viability in U937 cells
We evaluated the effect on viability of U937 leukemic cells
treated with both drugs. PTX, MG132, or PTX +MG132
induce inhibition of cell viability in time-dependent man-
ner (Figure 1). In the case of PTX or PTX +MG132
treated cells, these treatments at 18 hours exhibited simi-
lar behavior inducing around 60% of diminution of cell
viability (p < 0.05 vs all groups). These values practically
did not change in the other times. In contrast, at this same
time the cellular viability was slightly modified by MG132
treatment (p <0.05 vs other treated groups) and reached
similar values to those of the other two treated groups at
48 hours after treatment (optical density = PTX 0.48 ± 0.06,
MG132 0.54 ± 0.06, PTX +MG132 0.49 ± 0.11, p < 0.05 vs
untreated control group 1.87 ± 0.9).
PTX and MG132 proteasome inhibitor induce G1 cell
cycle arrest in U937 cells
Our next interest was to elucidate whether the combin-
ation PTX +MG132 modulates the cell cycle. To address
this point, U937 cells were treated in similar conditions
with PTX, MG132 or PTX +MG132 for 24 hours and,
subsequently, flow cytometry analysis of DNA content
to determine cell populations in the different cell cycle
phases was performed. As depicted in Figure 2, the per-
centage of untreated control group in G1 phase was
52.7 ± 3.8%. This percentage of cells is increased in PTX
treated group Δ% = 25% and the maximum increment
was observed in MG132 and PTX +MG132 treated
groups with nearly to Δ% = 45% for both groups p < 0.05.
For the S phase opposite results were observed, and it
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Figure 1 Evaluation of viability in U937 human leukemia cells treated with PTX, MG132 and PTX +MG132. U937 cells were incubated in
the presence of PTX, MG132, or PTX + MG132 for 18, 24, 36, and 48 hours as previously indicated. After incubation, WST-1 was added and 3 hours
later, viability was assessed by spectrophotometry at 450 nm. The results represent mean ± standard deviation of three independent experiments
performed in triplicate. Statistical analysis Mann-Whitney U test. ♦ p <0.05 PTX or PTX + MG132 vs untreated control group or MG132 group. ● p
<0.05 PTX + MG132 vs all groups. * p < 0.05 PTX, MG132 or PTX +MG132 vs untreated control group.
Table 1 Primer pair used for real-time (RT) quantitative PCR
Gene Primer pair sequences Gen bank accession No.
BAK 50CGC TTC GTG GTC GAC TTC AT 30 NM001188
50AGA AGG CAA AGA CTT CGC TTA 30
BAX 50TTT GCT TCA GGG TTT CAT CC 30 NM138764
50CAG TTG AAG TTG CCG TCA GA 30
DIABLO 50TGA CTT CAA AAC ACC AAG AGT A30 NM019887
50TTT CTG ACG GAG CTC TTC TA 30
DR4 50CTC GCT GTC CAC TTT CGT CTCT30 NM003844
50GTC AAA GGG CAC GAT GTT30
FAS 50TGA ACA TGG AAT CAT CAA GGA30 NM000043
50CAA AGC CTT TAA CTT GAC TT30
BCL-XL 50GCA GGC GAC GAG TTT GAA CT 30 NM138578
50GTG TCT GGT CAT TTC CGA CTG A 30
MCL-1 50CAC GAG ACG GTC TTC CAA GGA TGC T 30 NM021960
50CTA GGT TGC TAG GGT GCA ACT CTA GGA 30
SURVIVIN 50TGA GCT GCA GGT TCC TTA TCT G 30 NM001168
50GAA TGG CTT TGT GCT TAG TTT T 30
IkBa 50GGA TAC CTG GAG GAT CAG ATT A 30 NM001278
50CCA CCT TAG GGA GTA GTA GAT CAA T 30
P65 50GCA GGC TCC TGT GCG TGT CT 30 NM02975
50GGT GCT CAG GGA TGA CGT AAA G 30
RPL32 50GCA TTG ACA ACA GGG TTC GTA G 30 NM000994
50ATT TAA ACA GAA AAC GTG CAC A 30
Oligonucleotides were designed using the Oligo v.6 software. Gene sequences were obtained from the GenBank Nucleotide Database of the National Center for
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov).
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Figure 2 PTX and MG132 modulate the cell cycle in U937 cells. U937 cells were incubated alone or were treated with 8 mM PTX, 1 μM
MG132, or PTX +MG132 for 24 hours as previously indicated. After incubation the cell cycle was analyzed by flow cytometry. The results
represent mean ± standard deviation of three independent experiments performed in triplicate. Statistical analysis Mann-Whitney U test
* p <0.05 PTX, MG132 or PTX +MG132 vs untreated control group. ● p <0.05 MG132 or PTX + MG132 groups vs PTX or untreated control group.
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both drugs were - 26.4%, -49.2% and -54.3% respectively
p < 0.05. Finally for the G2 phase the percentage of cells
from untreated control group was 12.8 ± 3.6%, it dimin-
ished in treated groups Δ% = -15.2%, -24.5%, -10.9% for
PTX, MG132 and PTX +MG132 groups respectively.
These observations suggest that PTX and MG132 or its
combination induce a cell arrest in the G1 phase.
Apoptosis induction by PTX + MG132
At 24 hours of culture, apoptosis was evaluated in the
U937 human leukemia cells that was induced by the dif-
ferent treatments under experimental conditions as pre-
viously described. In Figure 3, it is observed that the
untreated control group showed a low percentage of
early and late apoptosis (2.1 ± 0.9% and 2.6 ± 1.1% re-
spectively) compared with the group treated exclusively
with either PTX (18.2 ± 2.1% and 28.5 ± 7.3% of early
and late apoptosis, respectively, p <0.05), or treated with
MG132 proteasome inhibitor so we observed 28.1 ± 8.1%
and 20.7 ± 6.6% of early and late apoptosis, respectively
(p < 0.05 vs untreated control group). It was also very in-


























Figure 3 Induction of apoptosis in U937 cells treated with PTX, MG13
culture medium or were treated with PTX, MG132, or PTX +MG132 for 24 h
The results represent mean ± standard deviation of three independent exp
groups vs untreated control group; ●p <0.05 PTX +MG132 vs all groups.to PTX +MG132 showed a greater percentage of late
apoptosis 44.1 ± 4.5% in comparison with all other
groups p <0.05.
PTX + MG132 induce mitochondrial membrane potential
(ΔΨm) loss
As mitochondria plays an important role in apoptosis, for
that reason we determined the ΔΨm in U937 leukemia
cells treated with PTX, MG132 or PTX +MG132 and the
results are represented in the Figure 4. The ΔΨm did not
change in untreated control group. However when the
cells were treated with either PTX or MG132 an import-
ant loss of the ΔΨm were noted 43.4 ± 4.7% and 46.8 ± 6.6
respectively (p < 0.05 compared with untreated control
group), and it is interesting that PTX+MG132 induce an
important ΔΨm loss in U937 cells 62.7 ± 3.7%, in com-
parison with the other groups p < 0.05.
PTX + MG132 increase cleavage in caspases-3, -9 and
cytochrome c release
We determined caspases -3, -8, -9 and cytochrome c by
Western blot. The analysis reveals that the combination














2 and PTX +MG132. U937 cells were incubated exclusively in RPMI-S
ours. After incubation apoptosis was assessed using Annexin V-FITC/PI.
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Figure 4 PTX +MG132 induces loss of the mitochondrial membrane potential (ΔΨm). U937 cells were cultured and treated with 8 mM PTX,
1 μM MG132, or PTX +MG132. After 24 hours, the cells were harvested and the ΔΨm was assessment by flow cytometry using DIOC6 staining.
Protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) was used as a positive control. The results represent mean ± standard deviation
of three independent experiments performed in triplicate. Statistical analysis Mann-Whitney U test. * p <0.05 all groups vs untreated control
group (UCG); ● p <0.05 PTX + MG132 vs all groups.
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serve that PTX increase cleavage of caspases-9 (2.8 fold)
and -3 (10.4 fold), and the release of cytochrome c (5.2
fold) compared with untreated control group p < 0.05. In
similar way MG132 proteasome inhibitor increase cleavage
of caspase-3 in 5.4 fold, caspase-9 in 1.7 fold and caspase-8
in 1.4 fold change and release of cytochrome c in 4.8 fold
compared with untreated control group p < 0.05. It is im-
portant to stress that when we used PTX+MG132 we ob-
served considerably cleavage of caspase-9 (13.5 fold) and
caspase-3 (13.4 fold) compared with PTX or MG132 aloneand with untreated control group, p < 0.05. In the same
way, when we use both drugs simultaneity we observed an
increase in the release of cytochrome c (5.11 fold) and
cleavage of caspase-8 (1.88 fold) in comparison with un-
treated control group p < 0.05.
Determination by flow cytometry of phosphorylated p65
protein from NF-κB, Bcl-2 and Bcl-XL antiapoptotic proteins
The phosphorylated p65 protein was quantified deter-
mining the Mean Fluorescence Intensity by flow cytome-
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Figure 5 Western blot analysis of caspases -3,-8,-9 and cytochrome c in U937 cells treated with PTX, MG132 or PTX +MG132. U937 cells
were cultured and treated with 8 mM PTX, 1 μM MG132, or PTX +MG132. After 24 hours, the cells were harvested and lysed. Equivalent amounts
of individual lysates were placed on 10% SDS gradient polyacrylamide gels for electrophoresis and then were electrotransferred to Immobilon-P
PVDF membranes. A representative study is shown and two additional experiments yielded similar results.
*
* *














Figure 6 Determination of phosphorylated p65 (NF-κB subunit)
in U937 cells treated with PTX, MG132 and PTX +MG132. U937
cells were incubated either alone or treated with 8 mM PTX, 1 μM
MG132, or PTX +MG132. After 1 hour, the phosphorylated p65
protein was determined by flow cytometry. For each sample at, least
20,000 events were acquired. The results represent mean ± standard
deviation of the Mean Fluorescence Intensity (MFI) of phosphorylated
p65 of three independent experiments carried out in triplicate. *p <0.01
vs the untreated control group.
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cells treated with PTX or the MG132 proteasome inhibi-
tor decrease the phosphorylation of p65 (p <0.05), and
in the combination of both compounds, this diminution is
more pronounced. The antiapoptotic proteins Bcl-2 and
Bcl-XL play a transcendent role in chemoresistance in
tumor cells; therefore, these proteins could be regulated
by the NF-κB transcription factor. For this, we studied the
effect of PTX and MG132 in these proteins. We can ob-
serve in Figure 7A that tumor U937 cells treated with
PTX, MG132, or PTX +MG132 in a similar manner re-
duce the expression of Bcl-2 protein in comparison with
the untreated control group (p <0.05). In the same way, in
Figure 7B, we can see that when U937 cells were treated
with the same schedule of treatments. We also observed a
reduction in Bcl-XL in comparison with the untreated
control group (p <0.05), with a tendency to be the most
pronounced in the group treated with both drugs. These
results together are according with apoptosis, caspases
cleavage, and cytochrome c release and ΔΨm loss experi-
ments and strongly suggest that assayed treatments
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Figure 7 PTX and MG132 reduce the expression of Bcl-2 and
Bcl-XL antiapoptotic proteins in U937 cells. U937 human
leukemia cells were incubated alone or were treated with 8 mM
PTX, 1 μM MG132, or PTX +MG132. After 24 hours the Bcl-2 (A) and
Bcl-XL (B)antiapoptotic proteins were determined by flow cytometry.
For each sample, at least 20,000 events were acquired. The results
represent mean ± standard deviation of the Mean Fluorescence
Intensity (MFI) of Bcl-2 or of Bcl-XL of three independent
experiments carried out in triplicate. *p <0.01 vs the untreated
control group.
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combination of the drugs.
Changes in the expression of proapoptotic, antiapoptotic,
and NF-κB-related genes
Real-Time PCR was employed to determine relative
change in gene expression (Figure 8). Arbitrary was con-
sidered as significant upregulation or downregulation
when the change was ≥ 30% in relation to constitutive
gene. In PTX-treated U937 cells, we found upregulation of
BAX, DIABLO, DR4, and FAS proapoptotic genes in com-
parison with untreated control group, and the most im-
portant upregulation observed with BAX (2.17-fold
upregulation). Similarly, PTX induces downregulation of
BCL-XL and MCL-1 antiapoptotic genes and of IκB and
p65 NF-κB-related genes. When U937 culture cells were
treated with the MG132 proteasome inhibitor, we ob-
served upregulation of BAX, DIABLO, and FAS genes. In
the case of antiapoptotic genes, MG132 induces down-
regulation of Survivin and p65 genes. When the cell cul-
tures were treated with PTX +MG132 we observedupregulation of the proapoptotic genes BAX with the
greatest upregulation (4.6-fold upregulation), and with FAS
and DIABLO genes. In relation to PTX +MG132-treated
U937 culture cells antiapoptotic genes BCL-XL, MCL-1,
and Survivin were downregulated as well as the NF-κB-re-
lated genes IκB and p65. In general, with these treatment
schedules the data suggest a balance in favor of proapop-
totic genes in U937 human leukemia cells treated with
PTX +MG132.
Discussion
In the present work, we studied the viability of U937 hu-
man leukemia cells treated with PTX and/or MG132
using the spectrophotometric assay of WST-1 as well as
apoptosis by flow cytometry. These results are in agree-
ment between them and with prior experiments clearly
showing that PTX and MG132 possess an important
antitumor activity per se, as has been reported [24,36].
This increasing in cytotoxicity when the drugs are added
simultaneously to tumor cell cultures in an important
manner, suggests an additive effect. In addition, the fact
of having found a clear effect of time-dose dependence
speaks to the specificity of the treatments. In this re-
spect, the potential of PTX and MG132 is great because
there reports of successful combinations of PTX with
antitumoral drugs such as adriamycin [8] and cisplatin
[23], and MG132 can synergize the antitumoral activity
of TRAIL receptor agonist [37] and propyl gallate [38].
In these sense our study conincide with these reports be-
cause we observe an important induction of late apop-
tosis (44.1%) when we use the combination PTX +
MG132 in U937 leukemia cells.
The growth arrest of tumor cells in G1 phase provides
an opportunity for cells to either undergo apoptosis or
induce cell repair mechanisms [39,40]. Interestingly, in
our study we observed with the different treatment ar-
rest in G1 phase and apoptosis induction. In this point
apparently the lower percentages of cells in S phase are
due to MG132 effect because the percentage of cells
treated exclusively with the proteasome inhibitor shows
the same values than the cells treated with PTX +
MG132, suggesting different action mechanisms be-
tween two drugs.
Based in the correlation of our observations related
with the ΔΨm loss, cytochrome c release, caspase assays
we think that apoptosis observed it is due principally to
the mitochondrial pathway. In addtion these results to-
gether are in aggremeent with previously reports [41,42].
It is known that PTX prevents the activation of NF-κB
by avoiding the breakdown of its inhibitory molecule, IκB
[43]; MG132 is also an NF-κB inhibitor as well as of the
proteasome [44]. We used both drugs in our experiments
in order to observe the modifications in p65 (NF-κB sub-























































































Figure 8 Expression of pro- and antiapoptotic genes in U937 cells treated with PTX, MG132 and PTX +MG132. U937 human leukemia
cells were incubated alone or treated with 8 mM PTX, 1 μM MG132, or PTX + MG132. After 3 hours gene expression was assessed by quantitative
Real-Time PCR. The data are expressed as messenger (mRNA) fold change in relative normalized quantities employing the RPL32 gene expression.
In all cases, standard deviation was not >0.08. Arbitrary was considered as significant upregulation or downregulation when the change was≥ 30%
in relation to constitutive gene expression.
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its combination compared with untreated cells (p < 0.05).
The fact that the experimental treatment induces a de-
crease in NF-κB phosphorylation allows us to suppose the
presence of important alterations in a mechanism that
promotes resistance to antitumor therapy [45,46].
We decided to study the Bcl-2 and Bcl-XL proteins
that possess antiapoptotic activity that can be regulated
by NF-κB activation [47,48]. In others tumor cells have shown
an overexpression of these proteins promoting a resistance to
radiotherapy or chemotherapy [49,50]. Likewise, some
studies have reported that various chemotherapeutic
agents commonly used upregulated Bcl-2 and Bcl-XL ex-
pression through the NF-κB-dependent pathway [51,52].
These proteins suppress apoptosis by preventing the acti-
vation of the caspases that carry out the process [53,54].
The susceptibility in U937 leukemia cells to apoptosis in-
duced by PTX and MG132, it can explain for the decrease
in the expression of Bcl-2 and Bcl-XL proteins when the
cells are expose to both drugs. Moreover the decrease in
the levels of Bcl-2 leads to ΔΨm loss potential. This fact is
key event for the apoptosis induction [55]. The data sug-
gest that PTX +MG132 treatment induces caspases-
dependent mitochondrial intrinsic pathway because we
found disruption in mitochondrial membrane potential,
cytochrome c release and an important cleavage of
caspases-9 and it is well known that it leads to caspase –3
cleavage and apoptosis induction [56]. Our result showthat the proapoptotic genes exhibited upregulation with
the different treatments and this tendency is observed
mainly in BAX, DIABLO, and FAS genes. Contrarily, the
antiapoptotic genes were downregulated, mainly BCL-XL,
MCL-1, and survivin.
It is important to stress that in relation to proapoptotic
genes study we found the highest upregulation in the BAX
gene and this is in agreement with our data in relationship
to the mitochondrial pathway participation observed in
this paper.
Above suggests that there is a gene balance that favors
apoptosis induction. We found a downregulation in the
IκB when leukemia cells were treated with PTX or PTX +
MG132 and in p65 genes when U937 leukemic cells were
treated with PTX, MG132, or its combination, suggesting
a diminution of the biological availability of these factors
that facilitate cell death.
Conclusion
Our results show that in this experimental model with
U937 human leukemia cells, PTX and MG132 showed an-
tileukemic activity, and together have an additive effect.
These drugs disturb the NF-κB pathway and induce cell ar-
rest in G1 phase, and decrease of antiapoptotic proteins
Bcl-2 and Bcl-XL and induce ΔΨm loss, cytochrome c re-
lease and a caspases-3,-9,-8 cleavage resulting in an increase
in apoptosis. In addition the different treatments gave rise
to equilibrium in favor of the expression of proapoptotic
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http://www.jbiomedsci.com/content/20/1/13genes. For these previously mentioned reasons, in general
our results support the idea that chemotherapy must be
administered under rational molecular bases.
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